Research Article

Association Study of Anticitrullinated Peptide Antibody Status with Clinical Manifestations and SNPs in Patients Affected with Rheumatoid Arthritis: A Pilot Study

Argul Issilbayeva,1,2 Bayan Ainabekova,1,2 Sanzhar Zhetkenev,1 Assel Meiramova,1,2 Zhanar Akhmetova,1,2 Karlygash Karina,1,2 Samat Kozhakhmetov,1 Madiyar Nurgazyiev,1 Laura Chulenbayeva,1 Dimitri Poddighe,3,4 Jeannette Kunz,3,4 and Almagul Kushugulova1

1Laboratory of Human Microbiome and Longevity, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan
2NJSC Medical University Astana, Department of Internal Medicine with the Course of Gastroenterology, Endocrinology and Pulmonology, Nur-Sultan, Kazakhstan
3Department of Medicine, Nazarbayev University School of Medicine (NUSOM), Nur-Sultan, Kazakhstan
4Department of Pediatrics, National Research Center for Mother and Child Health, University Medical Center, Nur-Sultan, Kazakhstan

Correspondence should be addressed to Argul Issilbayeva; isilbayeva.a@gmail.com

Received 24 March 2022; Accepted 25 April 2022; Published 11 May 2022

Academic Editor: Roberta Rizzo

Copyright © 2022 Argul Issilbayeva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology that leads to disability due to articular and extra-articular damage. RA prevalence is variable. The disease is most common among females with a 3 : 1 ratio. The interaction of environmental and host factors contributes to RA development. Currently, the genome-wide association studies (GWAS) give the opportunity to uncover the RA genetic background. Anticitrullinated peptide antibody (ACPA) is a highly specific RA antibody, associated with poor prognosis and severe course of RA, and regulated by numerous genes. Our study is aimed at investigating whether there are any clinical and genetic aspects correlate with ACPA presence in Kazakhstani patients with RA. Indeed, the available studies on this subject are focused on Caucasian and East Asian populations (mainly Japanese and Chinese), and there are scarce data from Central Asia. Methods. Our study included 70 RA patients. Patients' blood samples were collected and genotyped for 14 SNPs by real-time polymerase chain reaction (RT-PCR). General examination, anamnestic, and clinical and laboratory data collection were carried out. Statistical analysis was performed using R statistics. Results and Conclusion. Our study revealed a significant association of ACPA positivity with Fc receptor-like 3 (FCRL3) and ACPA negativity with signal transducer and activator of transcription 4 (STAT4) genes, but not with T cell activation Rho GTPase activating protein (TAGAP). In addition, ACPA positivity was associated with radiographic progression, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), age of RA onset, the patient global assessment, body mass index (BMI), and Gamma globulin. Conclusion. Remained 11 earlier identified significantly associated in Caucasian and Asian population SNPs were not replicated in our cohort. Further studies on larger cohorts are needed to confirm our findings with higher confidence levels and stronger statistical power.
1. Introduction

Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology that leads to disability due to articular and extra-articular damage. RA prevalence is variable. [1]. The disease is most common among females, making a ratio of 3:1 [2]. The interaction of environmental and host factors contributes to RA development [3]. The genetic factor is leading one [4, 5]. Currently, the genome-wide association studies (GWAS) give the opportunity to uncover genetic background of RA. The majority of pathogenetically crucial in RA development HLA and non-HLA genes have been revealed [6–10]. HLA DRB genes certainly occupied the background of RA. The majority of pathogenetically crucial in RA development HLA and non-HLA genes have been revealed [6–10]. HLA DRB genes certainly occupied the majority in RA etiopathogenesis [11]. The large-scale study by Okada et al. has presented more than 100 non-HLA RA gene loci, confirming their pivotal role in the RA development [10]. Among these genes, the most key and widely studied ones can be distinguished; moreover, a specific role in the RA pathogenesis is assigned to each of them. Accordingly, PADI2 (peptidyl arginine deiminase 2) promotes citrullination of proteins resulting in the conversion of arginine into citrullines [12]. Several risk factors affect T cell activation of function. These include CD28 and CD40, which affect T cell proliferation and proinflammatory cytokine synthesis [13, 14]. The CTLA4 (cytotoxic T-lymphocyte associated protein 4) sends the inhibitory signal to T cells and provides its regulation [15], STAT4 (signal transducer and activator of transcription 4) provides phosphorylation in response to proinflammatory cytokines and activates the transcription process under the interleukin-12 control [16], TAGAP (T cell activation Rho GTPase activating protein) regulates T-cell activation effecting its cytoskeleton [17], COG6 (component of oligomeric Golgi complex 6) provides a Golgi apparatus functioning [18], TRAF1 (tumor necrosis factor receptor-associated factor-1) encoding the certain protein of TNF superfAMILY mediates the antiapoptotic signals coming from TNF receptors [19], ETS1 (proto-oncogene 1, transcription factor) encodes a protein responsible of a large number of gene expression leading to stem cells and tumor process development [20], FCRL3 (Fc receptor like-3) encodes a protein that is an Fc receptor-like glycoprotein capable of influencing the activation of immunoreceptor-tyrosine [21], LBH (limb bud and heart development) regulates WNT signaling pathway [22], and the roles of LINC01104 (long intergenic nonprotein coding RNA 1104) and other genes are being investigated. Further studies aimed at validating early identifications; the overall average score was analyzed. The assess-ment of disease activity was carried out according to the DAS-28 disease activity index [42]. The functional disability was assessed by the health assessment questionnaire (HAQ). The X-ray stage was set according to the X-ray images of patients over the past year.

All patients underwent laboratory examination. Blood sampling was carried out strictly after a 12–14-hour period of fasting. All patients underwent general clinical research methods with the determination of indicators of the general blood test: the content of hemoglobin, erythrocytes, platelets, leukocyte formula, and erythrocyte sedimentation rate (ESR) according to Westergren and the determination of indicators of general urinalysis. biochemical blood tests determined the course of RA, as the presence of these antibodies is associated with the rapid development of deformities, visceral lesions, and comorbidities and a high risk of death [37–39]. The presence of these autoantibodies is also associated with an increase in disease activity measured by DAS28, X-ray progression, ultrasound of the joints, and a lower probability of achieving disease remission [40, 41]. Several studies have shown that the citrullination of proteins and the synthesis of autoantibodies, which underlies the origin of RA on the mucous membranes, are under genetic regulation [31–33]. Despite the large number of studies focusing on the genetic landscape of RA, most studies focused on Caucasian and East Asian (mainly Japanese and Chinese) populations. At present, studies on the Central Asian population are scarce. Nevertheless, the study of genetic markers associated with RA among various ethnicities opens up the opportunity to identify ethnic-specific RA risk genes, which may lead to the development of ethnic-specific diagnostic and therapeutic approaches. Moreover, while genetic predisposition has been investigated for RA in general, no studies focus on genetic markers linked to ACPA-positive RA.

2. Materials and Methods

2.1. Patients and Controls. 70 patients, all female, with the established RA diagnosis according to ACR/EULAR 2010 rheumatoid arthritis classification criteria [41], with the disease duration more than 1 year, were recruited in Nur-Sultan. The study was approved by the local ethics committee of National Laboratory Astana, Nazarbayev University, protocol No. 03-2019. Informed consent was obtained from all patients; the study was performed in accordance with the rules and principles of the Helsinki Declaration. All patients were examined by rheumatologists; all anamnestic and examination data were recorded in the individual cards. Examination of the bone and joint system was carried out according to the general accepted rules. The count of tender joint number (TJC) and swollen joint number (SJc) was carried out. The symptoms of transverse compression of the hands and feet and the strength of compression of the hands were evaluated. The deformities and disfigurements were recorded. Data on extra-articular manifestations and complication presence were recorded. The patient global assessment, indicated by marking a 10 cm line between very good and very bad state, was performed; the overall average score was analyzed. The assessment of disease activity was carried out according to the DAS-28 disease activity index [42]. The functional disability was assessed by the health assessment questionnaire (HAQ). The X-ray stage was set according to the X-ray images of patients over the past year.

Approximately two-thirds of RA patients produce anticitrullinated protein antibodies (ACPAs) [30–32]. These autoantibodies may be detected years before the onset of clinical symptoms, suggesting a role of autoantibodies in early RA development [33, 34]. Anti-ACPAs and anti-ACPA-negative RA can be regarded as two disease entities with different predisposing factors, etiology, disease severity, prognosis, and presumably pathogenesis [35, 36]. Furthermore, the presence of ACPA significantly worsens the course...
levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, protein fractions, creatinine, cholesterol, glucose, and C-reactive protein (CRP). Immunological parameters such as rheumatoid factor (RF) and antibodies to cyclic citrullinated peptide (ACPAs) were also determined. The blood samples were collected from all participants in compliance with infection safety measures.

2.2. SNP Analysis. Genomic DNA was extracted from the collected whole blood of RA patients and healthy subjects, to the test tubes with EDTA-ACD. The Promega Wizard genomic DNA Purification Kit was used to DNA isolation, according to manufacturer’s standard protocol. All DNA was stored at -20°C. The DNA concentration in isolated samples was determined using the NanoDrop 2000/2000c spectrophotometer (Thermo Fisher) and Qubit 2.0 using the dsDNA BR Qubit analysis kit (Thermo Fisher, catalog number 32853). The samples were genotyped for 14 SNPs (PAD2-rs761426, CD28-rs1980422, CD40-rs4810485, COG6-rs9603616, CTLA4-rs3087243, ETS1-rs73013527, FCRL3-rs2317230, LBH-rs10175798, LINC01104-rs9653442, RASGRF1-rs8032939, STAT4-rs11889341, SYNGR1-rs909685, TAGAP-rs2451258, TRAF1-rs3761847) and considered using standard borderline significance (p value lower than 0.05 was considered as statistically significant).

2.3. Statistical Analysis. The R ver 4.0.1 was used for statistical analysis: Chi square, t-test, and SNPassoc package. Comparison of genotype distribution and allele frequencies between RA patients and healthy controls was evaluated by the Chi-square (χ²) test and Fisher’s exact test, using an odds ratio (ORs) and 95% confidence intervals (95% CIs). Correlation of the associated SNP with autoantibody status among RA cases was performed with χ² test. Case and control genotype frequencies did not deviate from Hardy-Weinberg equilibrium. The comparison of the clinical and laboratory parameters with the different genotypes was performed using t-test and χ² test with Yate’s correction when necessary. A p value lower than 0.05 was considered as statistically significant. The adjusted significance level was considered using standard borderline significance p value of ≤ 0.05 and Bonferroni correction.

3. Results

3.1. Demographic Description of the Study Sample and Bivariate Analysis. Sample consisted of 34 ACPA-negative and 36 ACPA-positive patients (Supplementary Table 1). The mean age of the responders is 45 (39.25-50.75) years. The highest portion of the patients presents with moderate and high activity of RA. The average age of start of the disease in patients with rheumatoid arthritis is 35.11 years. The bivariate statistical tests show the significant associations of ACPAs with explanatory variables X-ray stage (p value = 0.017), RF status (p value = 0.00185), erythrocyte sedimentation rate (p value = 0.03218), age of RA onset (p value < 0.01), visual analog scale (p value < 0.01), BMI (p value < 0.01), and gamma globulin (p value < 0.01). Figure 1 shows the allele distribution of statistically significant single nucleotide polymorphisms. The major alleles are as follows: G (55.71%) in FCRL3 rs2317230, C (65.71%) in STAT4 rs11889341, and T (86.43%) in TAGAP rs2451258.

In Figure 2, the genotype distribution of statistically significant single nucleotide polymorphisms is illustrated. There is a more gradual distribution of sample in FCRL3 rs2317230 polymorphism than it is in STAT4 rs11889341 and TAGAP rs2451258 polymorphisms due to better recessive homozygous genotype distribution.

3.2. SNP Characteristics and Bivariate Analysis. Out of 14 SNPs of the patients tested, there was only one statistically significant result obtained using Hardy-Weinberg equilibrium (Supplementary Table 2). This can provide us with the assumption that samples are independent in 13 of the polymorphisms observed. COG6 gene SNP rs9063616 is found to violate the independence rule according to HWE and cannot be used in further analysis.

In Supplementary Table 2, the bivariate analysis between ACPA status and all the observed polymorphisms illustrates the statistically significant association in SNPs FCRL3 rs2317230, STAT4 rs11889341, and TAGAP rs2451258. Also, it is noticeable that polymorphism STAT4 rs11889341 is shown to have statistical significance with Bonferroni correction (Figure 3). It is possible to observe the significance (p value = 0.023549316) of G/T genotype in FCRL3 rs2317230 polymorphism with an overdominant mode of inheritance with odds ratio of 3.1 (1.14-8.48) (Table 1).
Regarding STAT4, the C/T-T/T genotype in dominant mode (0.29 (0.11-0.79)) and C/T genotype in overdominant mode of inheritance (0.21 (0.08-0.58)) were significantly associated with the ACPA-negative RA form (Table 2). Tests show significance in TAGAP rs2451258 codominant (p value = 0.046846672), dominant (p value = 0.014375636), overdominant (p value = 0.020765277), and log-additive (p value = 0.027666544) modes of inheritance (Table 3). Associations in SNP TAGAP rs2451258 are spurious due to relative small sample size and cannot be used to draw solid conclusions about its associations with ACPA, due to violation of Chi-square (χ²) test assumptions.

4. Discussion

Studies focusing on the genetic landscape of RA have contributed significantly to identifying genetic risk factors involved in disease development. Likewise, these studies also carry promise for future exploration of ethnic and racial differences in epidemiologic trends in RA, which have revealed significant variations in terms of RA incidence and prevalence worldwide. To begin to provide insight into the epidemiology of RA in Central Asia, we conducted the first pilot study to identify clinical and genetic linkages associated with ACPA, due to violation of Chi-square (χ²) test assumptions.

Partially consistent with this data, our study revealed a strong association of FCRL3 rs2317230 with the ACPA-positive form of RA, irrespective of RF status. However, researchers from Japan performed a meta-analysis of GWAS, which included 670 ACPA-negative RA patients and 16,891 controls and investigated a total of 1,948,138 markers. This study, which was followed by a replication study of the top 35 single nucleotide polymorphisms (SNPs)
using 916 RA cases and 3,764 healthy subjects, showed an association between FCRL3 rs17727339 and the ACPA-negative form of RA [43]. This result is distinct from our finding showing an association with ACPA-positive status, Our data on STAT4 association with RA are in accordance with several published studies. Meta-analyses by Tong et al. [47], Jiang et al. [48], and Ebrahimiyan et al. [49] demonstrated the association of STAT4 polymorphisms with RA susceptibility across major ethnic groups. However, the observed association in these studies was irrespective of ACPA or RF status, whereas our study revealed an association with ACPA positivity. This outcome is similar to studies in other ethnicities that reported STAT4 association with ACPA and RF status. For example, Egyptian researchers reported the association of STAT4 rs7574865 polymorphism with RF and ACPA positivity [50]. In addition, the STAT4 rs7574865 TT genotype in Syrian RA patients showed a potential impact on ACPA positivity [51]. Furthermore, a study performed by Ciccacci et al. that included 192 RA patients and 278 healthy individuals revealed STAT-4 association with a severe disease phenotype in terms of ACPA-positive status and radiographic damage in an Italian population [52].

Interestingly, there was also no significant association of polymorphisms in the PADI2 gene with the ACPA-positive form of RA in our study, despite the known key role of

| Table 1: Statistically significant SNP FCRL3 rs2317230 characteristics and bivariate statistics. |
|-----------------------------------------------|---------|---------|--------|--------|---------|---------|------|------|
| FCRL3 rs2317230 | ACPA- % | ACPA+ % | OR     | Lower  | Upper   | p value | AIC  |
| Codominant G/G    | 15      | 44.1    | 10     | 27.8   | 1       | 0.07679 | 97.9 |
|                  | G/T     | 9       | 26.5   | 19     | 52.8    | 3.17    | 1.03 | 9.77 |
|                  | T/T     | 10      | 29.4   | 7      | 19.4    | 1.05    | 0.3  | 3.68 |
| Dominant G/G     | 15      | 44.1    | 10     | 27.8   | 1       | 0.15291 | 98.9 |
|                  | G/T-T/T | 19      | 55.9   | 26     | 72.2    | 2.05    | 0.76 | 5.55 |
| Recessive G/G-G/T| 24      | 70.6    | 29     | 80.6   | 1       | 0.33037 | 100  |
|                  | T/T     | 10      | 29.4   | 7      | 19.4    | 0.58    | 0.19 | 1.75 |
| Overdominant G/G-T/T | 25   | 73.5    | 17     | 47.2   | 1       | 0.02355* | 95.9 |
|                  | G/T     | 9       | 26.5   | 19     | 52.8    | 3.1     | 1.14 | 8.48 |
| Log-additive 0,1,2| 34      | 48.6    | 36     | 51.4   | 1.11    | 0.6     | 2.06 | 0.72789 | 100.9 |

* refers to statistically significant p value < 0.05 (no adjustment). ** refers to statistically significant p value < 0.01 (no adjustment).

| Table 2: Statistically significant SNP STAT4 rs11889341 characteristics and bivariate statistics. |
|-----------------------------------------------|---------|---------|--------|--------|---------|------|------|
| STAT4 rs11889341 | ACPA- % | ACPA+ % | OR     | Lower  | Upper   | p value | AIC  |
| Codominant C/C    | 9       | 26.5    | 20     | 55.6   | 1       | 0.00716 | 93.1 |
|                  | C/T     | 23      | 67.6   | 11     | 30.6    | 0.22    | 0.07 | 0.62 |
|                  | T/T     | 2       | 5.9    | 5      | 13.9    | 1.12    | 0.18 | 6.93 |
| Dominant C/C     | 9       | 26.5    | 20     | 55.6   | 1       | 0.01268* | 94.8 |
|                  | C/T-T/T | 25      | 73.5   | 16     | 44.4    | 0.29    | 0.11 | 0.79 |
| Recessive C/C-C/T| 32      | 94.1    | 31     | 86.1   | 1       | 0.25659 | 99.7 |
|                  | T/T     | 2       | 5.9    | 5      | 13.9    | 2.58    | 0.47 | 14.31 |
| Overdominant C/C-T/T | 11  | 32.4    | 25     | 69.4   | 1       | 0.00169* | 91.1 |
|                  | C/T     | 23      | 67.6   | 11     | 30.6    | 0.21    | 0.08 | 0.58 |
| Log-additive 0,1,2| 34      | 48.6    | 36     | 51.4   | 0.6     | 0.28    | 1.26 | 0.16957 | 99.1 |

* refers to statistically significant p value < 0.05 (no adjustment). ** refers to statistically significant p value < 0.01 (no adjustment).
PADI2 and other PADI gene family members in the process of protein citrullination during RA development. Accordingly, a recent study by Guzmán-Guzmán et al. showed that PADI2 rs1005753 was associated with ACPA positivity and RF positivity in Mexican patients with RA [24]. Our study specifically investigating PADI2 rs761426 SNP association with ACPA-positive RA form and did not find any correlation. This result may thus indicate that various SNPs of one gene differ in their association with ACPA status in RA patients of diverse populations.

Recently, we published a study on HLA-DRB9, PADI4, and PTPN22 gene distribution in Kazakhstani RA patients, which revealed, among other data, an association of PADI4 with the ACPA-positive RA form and did not find any correlation. This result may thus indicate that various SNPs of one gene differ in their association with ACPA status in RA patients of diverse populations.

Our study demonstrates a significant correlation of FCRL3 with the ACPA-positive form of RA, whereas STAT4 showed a significant association with the ACPA-negative form. In contrast, TAGAP SNP association with ACPA status was spurious due to violation of Chi-square (χ²) test assumptions. Furthermore, 11 earlier identified SNPs as being significantly associated with ACPA status in Caucasian and East Asian populations were not replicated in our cohort. We recognize that the small sample size may be a major limitation of our study. A larger cohort of RA patients and an expanded number of SNPs will be needed to confirm our findings with higher confidence levels and stronger statistical power.

Nevertheless, our current results do not fully correlate with published studies conducted on Asian and European populations, which shows the need for further research into the epidemiology of RA.

### Data Availability

Data and material used during this study will be available from the corresponding author upon request.

### Additional Points

#### Study Limitation

We recognize that the small sample size may be a major limitation of our study. A larger cohort of RA patients, control group, and an expanded number of SNPs will be needed to confirm our findings with higher confidence levels and stronger statistical power.

#### Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Authors’ Contributions

AK and BA designed the research and critically revised the paper. AI, AM, KK, and ZhA performed the patient recruitment and clinical and laboratory examination. AI, MN, and LCh performed the research. SZh and AI analyzed the data. ZhK, DP, and AK provided the key technical support and critically revised the paper. AI and SZh wrote the paper. JK edited the paper.

| TAGAP rs2451258 | ACPA- % | ACPA+ % | OR | Lower | Upper | p value | AIC |
|-----------------|--------|--------|-----|-------|-------|---------|-----|
| **Codominant**  |        |        |     |       |       |         |     |
| T/T             | 22     | 64.7   | 32  | 88.9  | 1     | 0.04685 | 96.9 |
| C/T             | 10     | 29.4   | 3   | 8.3   | 0.21  | 0.05    | 0.84 |
| C/C             | 2      | 5.9    | 1   | 2.8   | 0.34  | 0.03    | 4.03 |
| **Dominant**    |        |        |     |       |       |         |     |
| T/T             | 22     | 64.7   | 32  | 88.9  | 1     | 0.01437*| 95  |
| C/T-C/C         | 12     | 35.3   | 4   | 11.1  | 0.23  | 0.07    | 0.8  |
| **Recessive**   |        |        |     |       |       |         |     |
| T/T-C/T         | 32     | 94.1   | 35  | 97.2  | 1     | 0.51842 | 100.6 |
| C/C             | 2      | 5.9    | 1   | 2.8   | 0.46  | 0.04    | 5.29 |
| **Overdominant**|        |        |     |       |       |         |     |
| T/T-C/C         | 24     | 70.6   | 33  | 91.7  | 1     | 0.02076*| 95.6 |
| C/T             | 10     | 29.4   | 3   | 8.3   | 0.22  | 0.05    | 0.88 |
| **Log-additive**|        |        |     |       |       |         |     |
| 0,1,2           | 34     | 48.6   | 36  | 51.4  | 0.34  | 0.12    | 0.97 |

* refers to statistically significant p value < 0.05 (no adjustment). ** refers to statistically significant p value < 0.01 (no adjustment).
Acknowledgments

Financial support for this study was supported from the grant AP08052703 "Determination of microbiomic and genomic biomarkers of rheumatoid arthritis in Kazakhstan population" of the Ministry of Education and Science of the Republic of Kazakhstan.

Supplementary Materials

Supplementary 1. Supplementary Table 1: description of clinical characteristics and bivariate analysis.

Supplementary 2. Supplementary Table 2: SNP descriptive statistics and bivariate analysis.

References

[1] J. S. Smolen, D. Aletaha, A. Barton et al., "Rheumatoid arthritis," Nature Reviews Disease Primers, vol. 4, p. 18001, 2018.

[2] W. J. Kovacs and N. J. Olsen, "Sexual dimorphism of RA manifestations: genes, hormones and behavior," Nature Publishing Group, vol. 7, no. 5, pp. 307–310, 2011.

[3] V. C. Romão and J. E. Fonseca, "Etiology and risk factors for rheumatoid arthritis: a state-of-the-art review," Frontiers in Medicine, vol. 8, pp. 1–20, 2021.

[4] G. S. Firestein and I. B. McInnes, "Immunopathogenesis of rheumatoid arthritis," Immunity, vol. 46, no. 2, pp. 183–196, 2017.

[5] D. van der Woude and M. A. H. M. van der Helm-van, "Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis," Best Practice & Research Clinical Rheumatology, vol. 32, no. 2, pp. 174–187, 2018.

[6] A. Ferreiro-Iglesias, A. Montes, E. Perez-Pampin et al., "Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept," PLoS One, vol. 14, no. 2, pp. 1–14, 2019.

[7] J. Kurkó, T. Besenyei, T. T. Glant, K. Mikecz, and Z. Szekanecz, "Genetics of rheumatoid arthritis - a comprehensive review," Clinical Reviews in Allergy & Immunology, vol. 45, no. 2, pp. 170–179, 2013.

[8] R. X. Leng, D. S. Di, J. Ni et al., "Identification of new susceptibility loci associated with rheumatoid arthritis," vol. 79, no. 12, pp. 1565–1571, 2020.

[9] S. Hayashi, T. Matsubara, K. Fukuda et al., "A genome-wide association study identifying the SNPs predictive of rapid joint destruction in patients with rheumatoid arthritis," Biomedical Reports, vol. 14, no. 3, pp. 1–7, 2021.

[10] Y. Okada, D. Wu, G. Trynka et al., "Genetics of rheumatoid arthritis contributes to biology and drug discovery," Nature, vol. 506, no. 7488, pp. 376–381, 2014.

[11] J. Karami, S. Aslani, A. Jamshidi, M. Garshashi, and M. Mahmoudi, "Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review," Gene, vol. 702, pp. 8–16, 2019.

[12] H. Yu, C. H. Tung, K. Y. Huang, H. B. Huang, and M. C. Lu, "The essential role of peptidylarginine deiminases 2 for cytokines secretion, apoptosis, and cell adhesion in macrophage," Apoptosis, and Cell Adhesion in Macrophage, vol. 21, no. 16, p. 5720, 2020.
PTPN22, and HLA-DRB9 genes distribution in the Kazakhstani Population,” Open Access Macedonian Journal of Medical Sciences, vol. 9, no. B, pp. 747–757, 2020.

[30] A. H. Hensvold, T. Frisell, P. K. E. Magnusson, R. Holmdahl, J. Askling, and A. I. Catrina, “How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins,” Annals of the Rheumatic Diseases, vol. 76, no. 1, pp. 119–125, 2017.

[31] Y. Ishikawa and C. Terao, “The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review,” Review, vol. 9, no. 2, p. 475, 2020.

[32] H. Ulrich, T. Häupl, and G. R. Burmester, “Citrullination: a specific target for the autoimmune response in rheumatoid arthritis,” vol. 195, no. 1, pp. 5–7, 2015.

[33] K. Salma, A. Nessrine, E. Krystel et al., “Rheumatoid arthritis: seropositivity versus seronegativity: a comparative cross-sectional study arising from Moroccan context,” Current Rheumatology Reviews, vol. 16, no. 2, pp. 143–148, 2020.

[34] M. M. J. Nielen, D. van Schaardenburg, H. W. Reesink et al., “Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 380–386, 2004.

[35] A. Tracy, C. D. Buckley, and K. Raza, “Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start?,” Seminars in Immunopathology, vol. 39, no. 4, pp. 423–435, 2017.

[36] A. Issilbayeva, A. Meiramova, A. R. Kushugulova et al., “The clinical course of rheumatoid arthritis in Kazakhstani patients,” Open Access Macedonian Journal of Medical Sciences, vol. 9, no. B, pp. 1352–1358, 2020.

[37] V. F. A. M. Derksen, T. W. J. Huizinga, and D. Woude, “The etiology of rheumatic diseases: a meta-analysis,” Journal of Autoimmunity, vol. 110, p. 102400, 2020.

[38] D. A. Fox, “Citrullination: a specific target for the autoimmune response in rheumatoid arthritis,” vol. 195, no. 1, pp. 5–7, 2015.

[39] K. Salma, A. Nessrine, E. Krystel et al., “Rheumatoid arthritis: seropositivity versus seronegativity: a comparative cross-sectional study arising from Moroccan context,” Current Rheumatology Reviews, vol. 16, no. 2, pp. 143–148, 2020.

[40] M. M. J. Nielen, D. van Schaardenburg, H. W. Reesink et al., “Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 380–386, 2004.

[41] A. Tracy, C. D. Buckley, and K. Raza, “Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start?,” Seminars in Immunopathology, vol. 39, no. 4, pp. 423–435, 2017.

[42] A. Issilbayeva, A. Meiramova, A. R. Kushugulova et al., “The clinical course of rheumatoid arthritis in Kazakhstani patients,” Open Access Macedonian Journal of Medical Sciences, vol. 9, no. B, pp. 1352–1358, 2020.

[43] V. F. A. M. Derksen, T. W. J. Huizinga, and D. Woude, “The role of autoantibodies in the pathophysiology of rheumatoid arthritis,” Seminars in Immunopathology, vol. 39, no. 4, pp. 437–446, 2017.

[44] O. Gadhelot, K. Hausotter, H. Eberle, T. Klink, and A. Pfeil, “Differing X-ray patterns in seronegative and seropositive rheumatoid arthritis,” Clinical Rheumatology, vol. 38, no. 9, pp. 2403–2410, 2019.

[45] J. Grosse, E. Allado, C. Roux et al., “ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography,” Rheumatology International, vol. 40, no. 4, pp. 615–624, 2020.

[46] J. Kay and K. S. Upchurch, “ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology,” Rheumatology, vol. 51, no. 6, pp. 5–9, 2012.

[47] M. L. L. Prevoos, M. Van T Hof, H. H. Kuper, M. A. Van Leeuwen, L. B. A. Van De Putte, and P. L. C. M. Van Riel, “Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, vol. 38, no. 1, pp. 44–48, 1995.

[48] C. Terao, K. Ohmura, Y. Kochi et al., “Anti-citrullinated peptide/protein antibody (ACPA) -negative RA shares a large proportion of susceptibility loci with ACPA-positive RA : a meta-analysis of genome-wide association study in a Japanese population,” Arthritis Research & Therapy, vol. 17, no. 1, pp. 1–11, 2015.